Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982

Online
ISSN
1437-4331
See all formats and pricing
In This Section
Volume 51, Issue 5 (May 2013)

Issues

Antibodies against Nε-homocysteinylated proteins in patients on different methods of renal replacement therapy

Marek Kolarz
  • Corresponding author
  • AVITUM Poland, Hemodialysis Unit Miechow ul. Szpitalna 3 32–200 Miechow, Poland
  • Email:
/ Jolanta Małyszko
  • Department of Nephrology, Medical University in Bialystok, Bialystok, Poland
/ Tomasz Stompór
  • Department of Nephrology, Hypertension and Internal Medicine, University of Warmia and Mazury, Olsztyn, Poland
/ Alicja Całka
  • Department of Nephrology, Hypertension and Internal Medicine, University of Warmia and Mazury, Olsztyn, Poland
/ Anetta Undas
  • Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
/ Michał Myśliwiec
  • Department of Nephrology, Medical University in Bialystok, Bialystok, Poland
Published Online: 2012-11-23 | DOI: https://doi.org/10.1515/cclm-2012-0527

Abstract

Background: High levels of antibodies against Nε-homocysteinylated (Nε-Hcy) proteins have been observed in patients on long-term hemodialysis (HD). We sought to investigate whether these antibodies are present in patients on peritoneal dialysis (PD) in comparable titers and to characterize the factors that determine levels of those antibodies in both patient groups.

Methods: The study involved 80 patients on HD and age- and sex-matched 75 subjects on PD. Serum IgG antibodies against Nε-Hcy-albumin and -hemoglobin were determined using in-house enzyme-linked immunosorbent assays. Total homocysteine (tHcy), folate, 8-isoprostaglandin F (8-iso-PGF) and paraoxonase-1 (PON-1) activity were also measured.

Results: Patients on PD and those on HD had similar levels of anti-Nε-Hcy-albumin [absorbancy at 490 nm: 0.571 (0.519–0.609) vs. 0.583 (0.523–0.625), p=0.41, respectively] and anti-Nε-Hcy-hemoglobin antibodies [0.659 (0.597–0.705) vs. 0.664 (0.597–0.722), p=0.60, respectively]. In both groups levels of the antibodies correlated with tHcy (r from 0.54 to 0.77, p<0.0001), 8-iso-PGF (r from 0.57 to 0.77, p<0.0001), and folate (r from −0.59 to −0.74, p<0.0001) levels, but not with the cause of renal disease, dialysis vintage, a history of coronary artery disease or PON-1 activity. In the multivariate logistic regression, after adjustment for potential confounders, plasma tHcy was the independent predictor of antibodies against Nε-Hcy-proteins irrespective of the method of dialysis.

Conclusions: Levels of antibodies against Nε-Hcy-proteins are similar in patients on long-term PD and HD. The level of tHcy is the only independent predictor of both antibodies irrespective of the dialysis method.

Keywords: autoantibodies; end-stage renal disease; homocysteine; protein homocysteinylation; renal replacement therapy

References

  • 1.

    Weir MR. Recognizing the link between chronic kidney disease and cardiovascular disease. Am J Manag Care 2001;17: S396–402.

  • 2.

    Stompór T, Olszewski A, Kierzkowska I. Can we prolong life of patients with advanced chronic kidney disease: what is the evidence? Pol Arch Med Wewn 2011;121:88–93. [PubMed]

  • 3.

    McCullough PA, Steigerwalt S, Tolia K, Chen S, Suying L, Norris KC, et al. Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP). Curr Diab Rep 2011;11:47–51. [Crossref] [PubMed]

  • 4.

    Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol 2003;14:415–24. [PubMed] [Crossref]

  • 5.

    Locatelli F, Marcelli D, Conte F, D’Amico M, Del Vecchio L, Limido A, et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 2001;12:2411–7. [PubMed]

  • 6.

    Helal I, Smaoui W, Ben Hamida F, Ouniss M, Aderrahim E, Hedri H, et al. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Saudi J Kidney Dis Transpl 2010;21:59–62.

  • 7.

    Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005;143:174–83.

  • 8.

    Van Biesen W, Vanholder R, Verbeke F, Lameire N. Is peritoneal dialysis associated with increased cardiovascular morbidity and mortality? Perit Dial Int 2006;26:429–34. [PubMed]

  • 9.

    Zoccali C, Enia G, Tripepi G, Panuccio V, Mallamaci F. Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients. Perit Dial Int 2005;25:S84–7.

  • 10.

    Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001;12:2181–9. [PubMed]

  • 11.

    Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninimiya T, Nigwekar SU, et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. Br Med J 2012;344:e3533. [Web of Science]

  • 12.

    de Koning L, Hu FB. Homocysteine lowering in end-stage renal disease: is there any cardiovascular benefit? Circulation 2010;121:1379–81. [Crossref] [PubMed] [Web of Science]

  • 13.

    Yilmaz FM, Yilmaz G, Duranay N, Parpucu H, Senes M, Tekeli N, et al. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Scand J Clin Lab Invest 2005;65:739–45. [Crossref] [PubMed]

  • 14.

    Perna AF, Satta E, Acanfora F, Lombardi C, Ingrosso D, De Santo NG. Increased plasma protein homocystinylation in hemodialysis patients. Kidney Int 2006;69:869–76. [PubMed] [Crossref]

  • 15.

    Jakubowski H. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol 2008;59:155–67. [PubMed]

  • 16.

    Undas A, Perla J, Lacinski M, Trzeciak W, Kaźmierski R, Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis. Stroke 2004;35:1299–304. [PubMed] [Crossref]

  • 17.

    Undas A, Jankowski M, Twardowska M, Padjas A, Jakubowski H, Szczeklik A. Antibodies to N-homocysteinylated albumin as a marker for early-onset coronary artery disease in men. Thromb Haemost 2005;93:346–50. [PubMed]

  • 18.

    Padjas A, Undas A, Swadzba J, Musiał J. Antibodies to N-homocysteinylated albumin in patients with systemic lupus erythematosus. Pol Arch Med Wewn 2007;117:80–5.

  • 19.

    Undas A, Kolarz M, Kopeć G, Glowacki R, Placzkiewicz-Jankowska E, Tracz W. Autoantibodies against N-homocysteinylated proteins in patients on long-term haemodialysis. Nephrol Dial Transplant 2007;22:1685–9. [Web of Science] [PubMed] [Crossref]

  • 20.

    Kolarz M, Wyroślak J, Zbróg Z, Kraśniak A, Rogulska J, Padjas A. Antibodies against N-homocysteinylated proteins and their determinants in patients on long-term hemodialysis. Pol Arch Med Wewn 2010;120:223–30. [PubMed]

  • 21.

    Undas A, Stępień E, Plicner D, Zieliński L, Tracz W. Elevated total homocysteine is associated with increased platelet activation at the site of microvascular injury: effects of folic acid administration. J Thromb Haemost 2007;5:1070–2. [Crossref] [Web of Science] [PubMed]

  • 22.

    Ząbczyk M, Głowacki R, Machnik A, Heród P, Kazek G, Jakubowski H, et al. Elevated concentrations of Nε-homocysteinyl-lysine isopeptide in acute myocardial infarction: links with ADMA formation. Clin Chem Lab Med 2011;49:729–35. [Web of Science]

  • 23.

    Naruszewicz M, Jankowska EA, Zymlinski R, Bukowska H, Millo B, Banasiak W, et al. Hyperhomocysteinemia in patients with symptomatic chronic heart failure: prevalence and prognostic importance – pilot study. Atherosclerosis 2007;194:408–14. [Web of Science]

  • 24.

    Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr 2006;136:1741–9.

  • 25.

    Undas A, Stępień E, Głowacki R, Tisończyk J, Tracz W, Jakubowski H, et al. Folic acid administration and antibodies against homocysteinylated proteins in subjects with hyperhomocysteinemia. Thromb Haemost 2006;96:342–7. [PubMed]

  • 26.

    Mekki K, Taleb W, Bouzidi N, Kaddous A, Bouchenak M. Effects of hemodialysis and peritoneal dialysis on redox status in chronic renal failure patients: a comparative study. Lipids Health Dis 2010;9:93. [PubMed] [Web of Science] [Crossref]

  • 27.

    Kose FA, Sezis M, Akcicek F, Pabuccuoglu A. Oxidative and nitrosative stress markers in patients on hemodialysis and peritoneal dialysis. Blood Purif 2011;32:202–8. [Crossref] [PubMed] [Web of Science]

  • 28.

    Johnson-Davis KL, Fernelius C, Eliason NB, Wilson A, Beddhu S, Roberts WL. Blood enzymes and oxidative stress in chronic kidney disease: a cross sectional study. Ann Clin Lab Sci 2011;41:331–9.

  • 29.

    Jakubowski H. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv Exp Med Biol 2010;660: 113–27.

  • 30.

    Wegner M, Pioruńska-Stolzmann M, Araszkiewicz A, Zozulińska-Ziółkiewicz D, Wierusz-Wysocka B. Evaluation of paraoxonase 1 arylesterase activity and lipid peroxide levels in patients with type 1 diabetes. Pol Arch Med Wewn 2011;121:448–54.

  • 31.

    Kolarz M, Głowacki R, Stompór T, Wyroślak J, Undas A. Elevated levels of Nε-homocysteinyl-lysine isopeptide in patients on long-term hemodialysis. Clin Chem Lab Med 2012;50:1373–8. [PubMed] [Web of Science]

  • 32.

    Gugliucci A, Kotani K, Kimura S. Paraoxonase 1 in chronic kidney failure. J Lipids 2012;2012:726048.

  • 33.

    Liberopoulos EN, Papavasiliou E, Miltiadous GA, Cariolou M, Siamopoulos KC, Tselepis AD, et al. Alterations of paraoxonase and platelet-activating factor acetylhydrolase in patients on peritoneal dialysis. Perit Dial Intern 2004;24:580–9.

  • 34.

    Forstermann U. Nitric oxide and oxidative stress in vascular disease. Eur J Physiol 2010;459:923–39.

  • 35.

    Konukoglu D, Firtina S, Serin O, Cavusoglu C. Relationship among plasma secretory phospholipase A2, oxidized low density lipoprotein and paraoxonase activities in hypertensive subjects treated with angiotensin converting enzyme inhibitors. Indian J Med Res 2009;129:390–4.

About the article

Corresponding author: Marek Kolarz, MD, PhD, AVITUM Poland, Hemodialysis Unit Miechow ul. Szpitalna 3 32–200 Miechow, Poland, Phone/fax: +48 41 3820290


Received: 2012-08-17

Accepted: 2012-10-25

Published Online: 2012-11-23

Published in Print: 2013-05-01



Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2012-0527. Export Citation

Comments (0)

Please log in or register to comment.
Log in